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Poster Session I 49stimulated with autologous LCL with or without MSC for 5 days.
The percentage of EBV-pentamer specific CTL was not affected
by the presence of MSC (mean 1.59% vs 1.52%). MSC did not in-
hibit IFN-g production by EBV-CTL (6039 6 1644 vs 5885 6
1608). Furthermore, cytolytic killing of LCL by EBV-CTL was
not suppressed by MSC (mean specific lysis 47 6 3.6% vs 52 6
4.7% at E:T ratio 30:1). Finally, we studied anti-CMV immunity
in 2 patiens who receivedMSC for acute GVHDof the gut evolving
into chronic GVHD, with a good transient response. PBMC from
these patients showed persistence of pp65-pentamer positive T-
cells and retained IFN-g response to CMV post MSC infusion
(mean SFC 91/105 PBMC pre-MSC, 113 at 2 weeks and 221 at 1
month post MSC infusion). Conclusion: MSC have little effect
on T-cell responses to CMV, EBV and Ad, which contrasts to their
strong immunosuppressive effects on alloreactive T-cells. These
data have major implications for immunotherapy of GVHD with
MSC and suggest that the effector functions of virus-specificT-cells
may be retained after MSC infusion.
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MAINTAININGTHE IN-VIVOHEMATOPOIETICNICHE IN-VITRO; ANOVEL
APPROACH TO STUDYING HEMATOPOEISIS IN BOTH A MURINE AND
A LARGE ANIMAL SYSTEM
Kraft, D.L., Smith, A., Weissman, I.L. Stanford University School of
Medicine, Stanford, CA; DRFV Foundation.
Introduction: INTRO: Hematopoietic Stem Cells (HSC) are
the most extensively characterized stem cell, yet understanding of
their niche, and the ability to maintain and expand HSCs in-vitro
remains a challenge. In vitro study of HSC has generally been lim-
ited to well-based cultures, or use of 3D structures, supplemented
with cytokines. As apposed to constructing an artificial niche, we
sought to examine whether the existent hematopoietic niche could
be maintained in-vitro and support HSC in-vitro, both in murine
long bones marrow fragments, & in perfused large animal vertebrae
and bone marrow cores. Methods: Femur and tibia from 3 month
old mice were harvested, and sectioned into 1/3rds ends removed to
facilitate perfusion of the bone marrow fragments (BMF). In addi-
tion, whole marrow ‘plugs’ were flushed from tibia. These were
then cultured in normal or low O2, in regularly changed media
1/- cytokines (Flt2, SCF, TPO). BMF were removed over time,
and analyzed by CFU assay and FACS for presence of HSC, &
transplanted into sublethally irradiated Ly5.2 recipients.
Large animal model: Fresh thoracic and lumbar vertebrae from
large juvenile swine were harvested and separated, then maintained
in culture as: non-perfused in media, syringe perfused by pump
from 0.5 to 1.5 ml/hr of media, or by surgically cannulated vertebral
artery and vein and maintained on a bioreactor. Vertebrae under-
went core biopsies every 1–2 days and were analyzed for viability
and by histology. Results: Murine BMF contained 35–72% viable
cells as measured by trypan blue exclusion at up to 14 days. In 4
to 11 day old BMF, a population of Slam1, KLS cells were detect-
able. In BMF transplanted recipients, donor derived cells were de-
tectable .4 months post transplant. Mean donor granulocyte
engraftment from BMF was 5.2 to 22.1%, compared to 19% from
an control BM cells, suggesting long-term engraftment was derived
from HSC maintained within cultured BMF. In porcine vertebral
bodies, non-perfused vertebrae had\10% viability by day 4 com-
pared to 20% viability if perfused by pump at .5 ml/hr or 49% via-
bility when perfused at .1 ml/hr. Histology revealed maintained
marrow structure and healthy appearing cells in marrow cores
from perfused vertebrae in contrast to unperfused marrow samples.
Conclusion:These results suggest that the intrinsicHSC niche can
be maintained in-vitro and further optimization of this approach
may provide a novel means to study murine and eventually human
HSC and niche in-vitro.
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ESTABLISHMENT OF BONE MARROW STROMA FROM PATIENTS AT PRE
AND POST-MOBILIZATION FOR AUTOLOGOUS PERIPHERAL BLOOD
STEM CELLS TRANSPLANTATION
Schimieguel, D.M.2, Silva, L.1, Dominato, J.A.3, Silva, M.R.R.4,
Nader, H.B.3, Borelli, P.5, Souza, M.K.2, Oliveira, J.S.R.2 1The Uni-versity of Texas MDAnderson Cancer Center, Houston, TX; 2University
Federal of Sao Paulo, Sao Paulo, Brazil; 3University Federal of Sao
Paulo, Sao Paulo, Brazil; 4University Federal of Sao Paulo, Sao Paulo,
Brazil; 5University State of Sao Paulo, Sao Paulo, Brazil.
Objective: Successful of autologous peripheral blood stem cell
transplantation relies on mobilization’s capacity of hematopoetic
progenitor cells frommarrow to blood stream.The aim of this study
was to evaluate the correlation between the velocity of establish-
ment and maintenance marrow’s stroma in vitro from mononuclear
cells and bone marrow biopsy data obtained before and after mobi-
lization treatment in hematologicmalignancies and controls.Mate-
rials and Methods: Were evaluated clinical data from 22 patients
and 10 healthy donors as controls regarding the velocity of estab-
lishment and maintenance of stroma through long-term bone mar-
row culture on semisolid medium and bone marrow
histopathological features. Results: Out of 32 samples harvested
at pre-mobilization, 21 (66%) achieve $70% confluency while 11
of 27 samples (34%) could do so after mobilization. At pre-mobili-
zation, 91% of samples that did not achieve confluency were from
patients. After mobilization, 9 (82%) and 2 (18%) samples from pa-
tients and controls reached confluency, respectively, indicating a re-
duction of stroma establishment potential, especially from controls
(p 5 0.03). We could not observe any difference between ‘‘good’’
and ‘‘poor’’ mobilizer in both times.Nevertheless, the velocity of es-
tablisment was faster from the controls than patients.Conclusions:
Patients with fibrotic or poor cellularity demonstrated lower capac-
ity of stroma’s establishing suggesting that damage might affect
most probably the marrow microenvironment than the hematopoi-
etic progenitors. However, a more reduction of stroma establish-
ment capacity disclosed in controls than patients after
mobilization might be due to a more intense mobilization in these
settings.HISTOCOMPATIBILITY/ALTERNATIVE
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATIONWITH REDUCED
INTENSITY CONDITIONING AND SIROLIMUS-BASED GVHD PROPHY-
LAXIS
Cutler, C.1, Kao, G.1, Ho, V.1, Alyea, E.1, Koreth, J.1, Armand, P.1,
Dey, B.2, Spitzer, T.2, Soiffer, R.1, Antin, J.H.1, Ballen, K.2 1Dana-
Farber Cancer Institute, Boston, MA; 2Massachusetts General Hospital,
Boston, MA.
Single-unit umbilical cord blood transplantation (UCBT) in
adults is associated with high transplant-related mortality, largely
due to delayed engraftment and infection. Double UCBT
(DUCBT) is associated with faster engraftment, but also with
high rates of acute GVHD. We studied DUCBT using sirolimus
and tacrolimus to improve GVHD outcomes.
Methods: Conditioning consisted of fludarabine (30 mg/m2 
6), melphalan (100 mg/m2  1), and rabbit ATG (1.5 mg/kg  4).
UCB units were $4/6 HLA-A, B, DR allele-matched with each
other and the recipient, and contained a minimum combined dose
of 3.7  107 TNC/kg pre-cryopreservation. GVHD prophylaxis
was tacrolimus (5–10 ng/ml) and sirolimus (3–12 ng/ml). Results:
29 patients (median 49 years, range 19–67) with .100 day follow-
up are reported. Diagnoses include AML(8), NHL(7), HD(5),
MDS(4), CLL/PLL(2), ALL(1), MPD (1) and CML(1). The me-
dian total cell doses prior to cryopreservation were 5.2  107
TNC/kg (range 3.7–7.6  107) and 12.5  106 CD341 cells (range
1.5–29.0 106). Neutrophil engraftment occurred at amedian of 21
days (range 13–70) and platelet engraftment occurred at a median of
42 days (range 25–162) after DUCBT. Three subjects did not attain
platelet transfusion independence by day 100 and there were 3 late
graft failures. 3 patients developed Gr. II-IV acute GVHD (2 Gr. II
and 1 Gr. III, median 21 days). Acute GVHD was less frequent
when compared with a prior DUCBT cohort that received cyclo-
sporine and MMF as GVHD prophylaxis (10.3% vs. 36.9%, p 5
0.04). Only 2 patients developed chronic GVHD after DUCBT.
50 Poster Session IThe median follow up is 13.5 months (15.2 months among survi-
vors, range 4.1–22.3 months). 100-day treatment-related mortality
was 10.3%, without any VOD or TMA. One and two year relapse-
free survival is 56.9% and 45.6% and overall survival is 74.8% and
69.8% at 1 and 2 years. Causes of death include sepsis(4), relapse(2),
and EBV-PTLD(2). Chimerism analysis at day 100 (n 5 23) re-
vealed complete single cord chimerism in 13 subjects with mixed
chimerism in 10. The first infused unit was the predominant unit
at day 100 in 15/23 subjects. There was no correlation between
cord dominance and HLA match, TNC/kg or CD341 cell count.
Conclusions: This study demonstrates excellent engraftment after
DUCBT using a reduced-intensity conditioning regimen. The risk
of acute and chronic GVHD are low when sirolimus and tacrolimus
are used as GVHD prophylaxis, and survival is comparable to his-
torical unrelated donor cohorts.131
BOTH KIR AND ITS LIGAND PLAY A ROLE IN HEMATOPOIETIC STEM
CELL TRANSPLANTS (HCT)
Sun, J.1, Palmer, J.2, Dagis, A.2, Oki, A.1, Gaidulis, L.1, Parker, P.1,
Nademanee, A.1, Rosenthal, J.3, Falk, P.5, Miller, M.4, Forman, S.1,
Senitzer, D.1 1City of Hope; 2City of Hope; 3City of Hope; 4Beckman Re-
search Institute; 5City of Hope, Duarte, CA.
Killer Ig-like receptors (KIRs) are expressed on human NK and
T cell subsets. KIRs transmit either inhibitory or activating signals
regulating cell activities. Some inhibitory KIRs specifically recog-
nize HLA-A, B, or Cw allotypes on target cells as inhibitory KIR
ligands (iKIRLs). Most activating KIR ligands have not yet to be
well defined. We have analyzed the known iKIRLs and KIR geno-
types in 544 primary allogeneic HCTs with T-replete grafts from
unrelated or HLA mismatched related donors. There were 159
transplants with class I antigen level mismatched donors; 79 cases
were without also being iKIRL mismatched; 80 cases were mis-
matched for the iKIRLs. The latter group had inferior overall sur-
vival (HR: 1.79; P 5 0.003), and event-free survival (HR: 1.86; P
5 0.001). Both relapse (HR: 1.90; P 5 0.03) and non-relapse mor-
tality (HR: 1.83; P 5 0.01) contributed to the inferior survival of
the group that were mismatched for both Class I and iKIRLs. The
detrimental effect was also evident when 8/8 antigen-matched
transplants (385) were analyzed for patients lacking iKIRLs. Over-
all survival in patients (218) lacking the HLA-Cw Group-1 or 2
iKIRL was significantly lower than that in patients (167) having
the iKIRLs, (HR: 1.39; P 5 0.02). Patients lacking iKIRLs had
higher non-relapse mortality (HR: 1.50; P 5 0.03). KIR genotype
data are available for 360 cases so far. Our algorithm calculates
a score based on the KIR genotype of the patient compared to
the KIR genotype of the donor. In 360 cases the score was found
to be predictive of the incidence of aGVHD (Table). Multivariate
analyses confirmed that both iKIRLs and KIR genotype scores
were independent factors affecting HCT outcomes. In T-replete
HCT, iKIRL mismatches, as well as the absence of iKIRLs confer
higher risk of a poor outcome. The algorithm for KIR genotype
scoring produces results that are predictive of the incidence of
aGVHD.
Correlation of SCORE and aGVHD
aGVHDScore 0 I II III IV III1(%).1 12 5 12 14 8 43
1 15 12 19 10 18 38
0 to 21 41 40 34 28 21 30
\21 34 12 12 8 7 21Chi Square test 5 0.00271.132
IMPROVED OUTCOMES OF PATIENTS WITH AML/MDS UNDERGOING
HAPLOIDENTICAL STEM CELL TRANSPLANTATION USING FLUDARA-
BINE, MELPHALAN AND THIOTEPA CONDITIONING CHEMOTHERAPY
Ciurea, S.O., Quareshi, S., Rondon, G., McMannis, J., Pesoa, S.,
Cano, P., Fernandez-Vina, M., Giralt, S., de Lima, M.,
Champlin, R.E., Gajewski, J. The University of Texas MD Anderson
Cancer Center, Houston, TX.
Background: Total body radiation (TBI) conditioning is associ-
ated with substantial toxicity in patients (pts) undergoing haploi-
dentical stem cell transplantation (HaploSCT). We evaluated
a chemotherapy-only reduced-intensity conditioning (RIC) regi-
men to elicit engraftment with less toxicity in patients with AML/
MDS treated with HaploSCT and report a non-randomized com-
parison between FMT and TBI regimens for such patients.
Methods: 31 pts underwent HaploSCT with CD34-selected
PBPC. 18 pts received a RIC consisting of melphalan 140 mg/m
sq on day -8, 10 mg/m2, thiotepa on day -7, 160 mg/m2, fludarabine
on days -6, -5, -4, -3 and 1.5 mg/kg of rabbit ATG on days -6, -5, -4,
and -3 (FMT) between 10/2001–4/2007, and 13 pts who received
thiotepa 5 or 10 mg/kg on day -8, cyclophosphamide 60 mg/kg
on days -7 and -6, ATG 15 mg/kg on days -4 and -3 and TBI
3Gy/day on days -4 to -1 (CTT) between 4/1995–2/2000. The me-
dian age was 36 and 35 years respectively. Cytogenetics were poor
or intermediate-risk with the poor-risk present in 55.5% of FMT
and 43% CTT pts. At the time of transplant 61.1% of FMT and
53.8% of CTT pts had relapsed/refractory disease. Pts had 2 or
3-antigen mismatched donors with 3-antigen mismatch in 77%
FMT and 53.8% CTT pts. The numbers of CD34 cells infused
were 11 and 7.3  106/kg (p 5 0.4), and CD3 cells were 0.01 and
0.85  104/kg (p 5 0.1) in the FMT and CTT groups. 4 out of
13 pts in the CTT group also received psoralen-phototherapy
treated T-cells. Results: Median follow-up in FMT pts was 30.5
months. 77.8% and 71.4% of the pts engrafted with FMT and
CTT regimens. Grade 3–4 aGVHD occurred in 5.5% and 57.1%
(p 5 0.002) while cGVHD was found in 27.7% and 42.5%
(p5NS). Early death occurred in 1 FMT and 6 CTT pts (p 5
0.018) while day 100 TRM was 16.6% versus 53.5% (p 5 0.028).
OS was 33.3% and 14.3% (p5 0.06). 4 out of 7 (57%) FMT treated
pts in CR at the time of transplant survived as compared with 2 out
of 11 pts (18.1%) not in CR (p 5 0.03). None of the 6 pts in CR
treated with CTT survived (p 5 0.03). NRM was 33% in the
FMT group and 69% in the CTT group. 1 pt died of GVHD in
the FMT group as compared with 4 in the CTT group. Other
causes of death were disease relapse in 6 pts, organ failure and infec-
tions in 5 pts in the FMTgroup, while 3 pts died of recurrent disease
and 4 of infection and organ failure in the CTT group.
In conclusion, the RIC FMT regimen was an effective, less toxic
preparative regimen for patients with AML undergoing HaploSCT.133
A RETROSPECTIVE STUDY AND MATCHED PAIR ANALYSIS OF 240 PEDI-
ATRIC PATIENTS WITH MALIGNANCIES TRANSPLANTED WITH PLASMA
DEPLETED (PD) OR RED CELL REDUCED (RCR) CORD BLOOD (CB)
PRODUCTS
Graham, M.1, Fiederlein, R.1, Wang, B.2, Rosenthal, J.3, Karanes, C.3,
Nademanee, A.3, Jaing, T.-H.4, Chan, L.L.5, Tan, P.-L.6, Gjertson, D.7,
Petz, L.2,7, Chow, R.2,8 1Univ of Arizona Med Ctr, Tucson, AZ; 2Stem-
Cyte International Cord Blood Ctr, Arcadia, CA; 3City of Hope National
Medical Center, Duarte, CA; 4Chang Gung Children’s Hosp & Univ,
Linkou, Taiwan; 5Univ of Malaya Med Ctr, Kuala Lumpur, Malaysia;
6National Univ Hosp, Singapore; 7UCLA Sch of Publ Health, Los An-
geles, CA; 8StemCyte Taiwan National Cord Blood Center, Linkou, Tai-
wan.
Cell dosage is critical for cord blood transplantation (CBT) out-
come; therefore pediatric patients are ideal for CBT. Younger re-
cipient age is associated with better survival and neutrophil
(ANC500) engraftment. Outcome is furter improved by increasing
CB cell dose. Most CB banks practice red blood cell (RBC) reduc-
tion, which incur significant nucleated and progenitor cell loss after
processing. One way to minimize cell loss and reduce volume is to
